Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 6, 2000

View Archived Issues

CV Therapeutics' CVT-3146 enters phase I testing

IGT Pharma signs agreement with NTB to facilitate merger

Antizol approved in Canada for treatment of ethylene glycol poisoning

NeoTherapeutics expands scope to include cancer therapy; subsidiary established

Inflazyme reports company progress in quarterly shareholder letter

Magnesium sulfate emerges as a potential therapy for stroke

Series of nicotinic acetylcholine receptor ligands claimed by NeuroSearch

Researchers at RCT discover novel compounds for degenerative bone disorders

International patent issued to Sanofi-Synthelabo for new anticoagulants

Novel series of vitronectin receptor antagonists claimed by BASF

NPY antagonists and their use in obesity described by Pfizer

Specific CRF1 ligands designed at Neurogen

Water-soluble antifungal agents from Janssen display potent, broad-spectrum activity

Refractory/relapsed diffuse large B-cell NHL responds well to epratuzumab

Company Profile: Pozen

SB-251353-stimulated neutrophils show enhanced bactericidal activity

Roche and deCODE Genetics identify chromosomal location of osteoporosis gene

Phase I study results reported in San Francisco for MEDI-507 in GVHD

Company Profile: Keryx Biopharmaceuticals

Progen completes patient recruitment for phase Ib trial of PI-88 in cancer

Higher doses of interferon beta-1a offer no additional clinical benefit for MS patients

NaPro BioTherapeutics in-licenses technology for altering genes, sets up genomics division

Antigenics expands pancreatic cancer phase I/II trial following positive data with Oncophage vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...